Evidence of Increased 3-Alpha-Androstanediol Glucuronide in Female Pattern Alopecia: A Cross-Sectional Observational Study Evaluating Ovarian, Adrenal, and Peripheral Androgens

This study concluded that the Free Androgen Index (FAI) could serve as a reliable biomarker for hyperandrogenism in women with androgenetic alopecia, showing more predictive value than testosterone or SHBG alone.

In this study, researchers described hyperandrogenism as a condition resulting from excessive androgen production, which can lead to symptoms like acne, hirsutism, and hair loss, particularly relevant for dermatological evaluation and management in adult females.

This study observed that adult female acne may be associated with hyperandrogenic features and polycystic ovary syndrome, though routine hormonal tests often do not show abnormalities other than PCOS.

This review offers evidence-based recommendations for diagnosing and treating female pattern hair loss, emphasizing clinical assessment and starting treatment with minoxidil, while noting that measurement of certain hormones and vitamins is optional.

This study found that women with female pattern hair loss had increased 5α-reductase isozymes and decreased aromatase mRNA levels, potentially affecting their response to treatment.

This study found that ethinylestradiol and high-dose cyproterone acetate significantly reduced hirsutism scores and were effective for treating acne and alopecia in women with hyperandrogenism.

This study found that trichoscopy criteria can distinguish female androgenic alopecia from chronic telogen effluvium, with specific features achieving 98% diagnostic specificity.

This study found that the prevalence of androgenetic alopecia increases with age among both men and women in Maryborough, Australia, with 57% of women and 73.5% of men aged 80 and over affected.

This study found that women with symptoms of oligomenorrhoea and/or hirsutism are more likely to have polycystic ovaries and less favorable biochemical and clinical markers compared to asymptomatic women.

This study found that women with androgenic alopecia had a higher prevalence of polycystic ovarian morphology and higher androgen levels compared to controls, suggesting a strong association with PCO.

This study found that women with androgenetic alopecia showed higher levels of certain hormones and lower levels of sex hormone-binding globulin than healthy controls, potentially linking these factors to alopecia severity.

This study found that finasteride effectively reduced hirsutism in women during 12 months of treatment, with some effects persisting in the majority after stopping the medication.

This study suggests that in women with androgenic alopecia and men with premature balding, enhanced 5α-reductase activity and altered androgen conjugation, favoring sulfurylation, may be involved in scalp hair loss.

This study found that women with female pattern androgenic alopecia have significantly higher levels of certain androgens and androgen sulfates compared to normal premenopausal women, suggesting markers for diagnosis and treatment efficacy.

This paper reviews current knowledge about androgens' role in androgenic alopecia and female hirsutism but presents no new clinical findings.

This study found that women with female pattern baldness had a marked increase in the 3α,17β-androstanediol glucuronide/sex hormone binding globulin ratio and low serum sex hormone binding globulin.

In this study, women with diffuse alopecia were found to have higher serum levels of adrenal androgen DHEAS, which may contribute to disrupted scalp hair growth.

This study found that plasma 3 alpha-diol glucuronide was markedly elevated in women with idiopathic hirsutism, suggesting it may be a marker of peripheral androgen action.

This article presents a classification system for stages of female-pattern androgenetic alopecia to aid early diagnosis and mentions existing systems for rare male-pattern cases, but reports no new clinical results.